Completed PHASE3 INTERVENTIONAL 1-arm NCT02163499

Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months

Multicenter, Multi-Dose, Open-Label Maintenance of Long-Term Safety and Efficacy of Sodium Zirconium Cyclosilicate (ZS) in Hyperkalemia

Sponsor: ZS Pharma, Inc.

Conditions Hyperkalemia

Interventions Sodium Zirconium Cyclosilicate

Updated 8 times since 2017 Last updated: May 29, 2018 Started: Jun 30, 2014 Primary completion: Nov 30, 2016 Completion: Nov 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hyperkalemia, this trial is completed. The trial is conducted by ZS Pharma, Inc. and has accumulated 8 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jul 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jul 2018 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Jun 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ZS Pharma, Inc.

Data source: ZS Pharma, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Berlin, Germany , Brandon, United States , Cape Town, South Africa , Chattanooga, United States , Chesterfield, United States , Chula Vista, United States , Columbus, United States , DeLand, United States , Denver, United States and 38 more locations